Teleflex Incorporated

NYSE:TFX

Medical - Instruments & Supplies

Healthcare
$165.85 +0.83%

+$1.04 today

Market cap
$6.58B
Beta
0.82
P/E (TTM)
-5.5
EPS (TTM)
-$22.79
Dividend yield
1.08%
52W Low $100.18High $139.67

Volume 1.16M

Average 0.80M

TFX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Teleflex IncorporatedNYSE: TFX

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development grows, but more slowly than its trailing trend

Q2 FY2026 research & development of $45.12M rose 17.1% year over year, behind the +23.6% change in trailing-twelve-month research & development. Sequentially, it rose 1.7% from the prior quarter. Over 3 fiscal years it compounded at -2.0% a year.

Context

  • Research & development amounted to 7.3% of revenue in FY2025, up 2.0 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +17.1% toward the trailing-twelve-month pace of +23.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$45.12M+1.7% QoQ
Last fiscal yearDec 2025
$144.78M-10.4% YoY
LTMJun 2026
$195.47M+23.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+17.1%——
1 year-10.4%——
3-year CAGR-2.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
144.78M USD
Year-over-year change
-10.4%
4-year CAGR
+2.6%

Research & Development vs competitors

How TFX compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +23.6% is the 4th highest of 11, against a peer median of +9.4%.
  • Research & development amounts to 7.5% of revenue for TFX, versus a peer median of 24.5%.
TFX Competitors
Research & Development for TFX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PCVXVaxcyte, Inc.LTM Jun 2026$1.03B USD+74.2%+67.4%—
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$739.14M USD+21.7%+29.3%164.0%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$433.31M USD-14.7%-11.3%43.0%
ALKSAlkermes plcLTM Sep 2026$430.42M USD+49.7%+5.9%24.5%
BLCOBausch + Lomb CorporationLTM Jun 2026$404M USD+12.5%+6.5%7.6%
CRSPCRISPR Therapeutics AGLTM Sep 2026$283.28M USD+1.6%-16.9%1125.4%
TGTXTG Therapeutics, Inc.LTM Sep 2026$236.22M USD+65.3%+8.5%26.3%
TFXTeleflex IncorporatedLTM Jun 2026$195.47M USD+23.6%-2.0%7.5%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$96.93M USD+1.0%+8.8%6.0%
KRYSKrystal Biotech, Inc.LTM Jun 2026$59.23M USD+6.3%+11.0%13.4%
STVNStevanato Group S.p.A.LTM Jun 2026€25.44M EUR+5.3%-10.8%2.1%
Peer median (excluding TFX) —+9.4%+7.5%24.5%

Competitors are the stored peer set for TFX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.81B2.79B2.97B3.05B1.99B
Cost of Revenue1.26B1.26B1.33B1.34B871.96M
Gross Profit1.55B1.53B1.65B1.7B1.12B
Gross Margin55.2%54.9%55.4%55.9%56.2%
Research & Development130.84M153.82M154.35M161.67M144.78M
Selling, General & Admin860.09M863.75M929.87M995.27M720.17M
Operating Expenses921.51M1.03B1.14B1.55B864.95M
Depreciation & Amortization237.36M230.59M242.12M274.6M177.74M
EBITDA853.8M730.77M761.21M433.62M302.51M
EBITDA Margin30.4%26.2%25.6%14.2%15.2%
Operating Income628.1M499.73M506.31M151.01M255.8M
Operating Margin22.4%17.9%17.0%5.0%12.8%
Interest Income1.33M912K12.78M8.01M6.4M
Interest Expense56.97M54.26M85.08M83.54M100.22M
Other Income / Expenses(68.63M)(53.81M)(72.3M)(75.54M)(231.25M)
Income Before Tax559.47M445.92M434.01M75.48M24.55M
Pre-Tax Margin19.9%16.0%14.6%2.5%1.2%
Income Tax Expense74.35M83M76.44M5.32M(33.98M)
Net Income485.37M363.14M356.33M69.68M(905.64M)
Net Margin17.3%13.0%12.0%2.3%-45.4%
EPS (Basic)10.387.747.581.49(20.30)
EPS (Diluted)10.237.687.531.48(20.25)
Weighted Avg Shares46.77M46.9M46.98M46.84M44.62M
Weighted Avg Shares (Diluted)47.43M47.31M47.3M47.09M44.72M

Teleflex Incorporated

NYSE:TFX

Intrinsic Alpha fair value

Locked

Current Price

$165.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.